About microRNAsTherapeutic OpportunitiesDrugs & Technologies

Careers

Overview

Join Our Effort To Develop Drugs That Target The Pathways Of Human Disease

Regulus Therapeutics Inc. is a biopharmaceutical company leading the discovery of innovative new medicines based on microRNAs. Regulus is advancing microRNA therapeutics in several areas including hepatitis C infection, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus was established in September of 2007 by Alnylam Pharmaceuticals (Nasdaq:ALNY) and Isis Pharmaceuticals (Nasdaq:ISIS) and benefits substantially from their RNA therapeutic drug expertise. In April 2008, Regulus formed an alliance with GlaxoSmithKline to explore microRNA therapeutics for immuno-inflammatory diseases. In February 2010, GSK and Regulus Therapeutics announced a new collaboration to develop and commercialize microRNA therapeutics targeting microRNA-122 for the treatment of Hepatitis C Infection. In June 2010, sanofi-aventis and Regulus Therapeutics entered into the largest-to-date strategic alliance on microRNA therapeutics.

Regulus is located in Torrey Pines, California and has a seasoned executive team experienced in corporate management, business, science, and drug discovery and development.


Regulus seeks highly motivated, innovative and passionate team members for the following positions:

top

Featured Publication

Nature Collections

Nature Collections
This collection showcases the latest papers from Nature that explore the biogenesis, biological effects in both normal and diseased cells, and therapeutic potential of miRNAs.

Read More


Publications

Regulus Publications

Isis and Alnylam scientists and collaborators were the first to discover microRNA antagonist strategies that work in vitro and in vivo in animal studies.

View Our Publications